

Key Management appointments at Rhythm Biosciences



22 May 2018, Melbourne: Medical diagnostics pioneer Rhythm Biosciences Limited (ASX: RHY) has bolstered its management team by appointing experienced health sector executive Glenn Gilbert as Chief Operating Officer.

For the past eight years Mr Gilbert has held various roles at the ASX listed pharmaceutical and device maker Medical Developments International, most recently as head of sales and marketing with oversight of global product commercialisation.

His experience also includes mergers and acquisitions and managing intellectual property.

Previously, Mr Gilbert held leadership roles at CSL's biotherapeutics arm, now known as Seqirus.

In addition, Mr Gilbert holds a Monash University Bachelor of Science qualification, as well as a Graduate Certificate in Corporate Management and a Masters of Business Administration (both from Deakin University)

We're also pleased to announce the appointment of Dr Joanne Boag as General Manager – Commercial.

Dr Boag has 14 years' experience in the health and medical research fields, including a decade of experience in commercialising technologies, most recently working within medical research institutes to improve and develop research programs and commercialise early-stage technologies.

A registered Australian patent and trade mark attorney, Dr Boag spent more than five years in private practice at a specialist IP firm. She also has a PhD in molecular biology from the University of Western Australia.

Mr Gilbert and Dr Boag join an experienced management team and work closely with General Manager of RHY's ColoSTAT product Craig Lewis who was appointed in June last year. Mr Lewis has spent over a decade leading innovative projects within the complex biomedical device regulatory environment including as a consultant at well-known medical device commercialisation company Planet Innovation. He has held key early-stage development roles at start-ups including leading a design team to achieve an on-market, award-winning medical device platform and consumable system.

Mr Lewis is named as an inventor on four granted patents and has a Bachelor of Engineering with first class Honours and a Bachelor of Science from the University of Melbourne.

CEO Trevor Lockett has wide experience in multidisciplinary research including prostate cancer gene therapies and colorectal cancer prevention.

“Both Glenn and Joanne come with excellent pedigrees,” Mr Lockett said. “Their broad and relevant experience will be invaluable to the company as we move to commercialise our simple and effective test for early detection of colorectal cancer.”

Rhythm remains on track to complete the cloning of its four mixed monoclonal antibody preparations by the end of June as a component of its broader objective to develop its own antibodies and target proteins to give it control of the supply, quality and cost of its key reagents. This is a key early milestone and we expect to fulfil this within a few months. These are the preconditions for the reliable manufacture of test kits with consistently high diagnostic performance properties.

Ends

TREVOR LOCKETT
MANAGING DIRECTOR
0418 647 490

SHANE TANNER
CHAIRMAN
0411 107 099

About Rhythm Biosciences

Rhythm Biosciences is developing and commercialising Australian medical diagnostics technology for sale across national and international markets.

Rhythm’s lead product, ColoSTAT™, is intended to provide accurate and early detection of colorectal cancer, acting as either a first-step screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or colonoscopy. As well as being of value to those with risk factors associated with colorectal cancer, ColoSTAT™ provides an alternative for those who choose not to or are unable to be assessed using standard screening programs.

Being developed to be an affordable and effective diagnostic, ColoSTAT™ has the potential to play an important role in reducing morbidity, mortality and healthcare costs associated with colorectal cancer.